Cogstate Ltd · ASX:CGS
Cogstate — Corporate Update (January 2025)
16 slides from Cogstate's corporate update, Jan 20, 2025
Slide 1: 1H25 Business Update – Investor Presentation Materials
ASX Announcement 20 January 2025 1H25 Business Update – Investor Presentation Materials Cogstate Ltd (ASX:CGS) has today provides an update in respect of financial performance for the half-year ended 31 December 2024 (1H25) based on unaudited results, including the attached investor presentation mat
Slide 2: About Cogstate
About Cogstate Cogstate Ltd (ASX:CGS) is the neuroscience technology company optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerised cognitiv
Slide 3: Investor Update
Investor Update 20 January 2025 © 2025 Cogstate Ltd. All rights r eserved.
Slide 4: Disclaimer
Disclaimer This presentation has been prepared by Cogstate Limited (‘Cogstate’). The information in this presentation is of a general na ture and does not purport to be complete, nor does it contain all the information which would be required in a prospectus prepared in accordance with the requireme
Slide 5: Background Information
Background Information Market Cap A$180m (US$110m) Major shareholders: Shares on issue 171.9m • Dolby family (Dolby Labs, San Fran) 17% Options on issue 7.6m • Myer family (Chairman) 14% Performance Rights on issue 5.6m • Aust Ethical Investment (Sydney) 10% • Anacacia Capital (Sydney) 9% Cash US$34
Slide 6: FY25: First Half Growth
FY25: First Half Growth All figures in US$ 1H25 based on unaudited results 1H25 2H24 1H24 Total Revenue $23.9m $23.3m $20.2m - Clinical Trials Revenue $22.7m $21.5m $17.9m - Healthcare Revenue * $1.2m $1.7m $2.2m Clinical Trials Sales Contracts Executed $20.3m $16.0m $10.9m Cash & Cash Equivalents $
Slide 7: Clinical Trials Revenue, by Half Year
Clinical Trials Revenue, by Half Year 24 1H25 22 Clinical Trials Revenue $22.7m, up 27% 20 • Clinical Trials revenue has returned to growth over the last 12 months 18 US$ Million • 1H25 result continues growth trend 16 from 2H24 14 • Clinical Trials revenue is 95% of total 12 revenue 10 8 6 1H20 2H2
Slide 8: Clinical Trials Revenue, by Calendar Year
Clinical Trials Revenue, by Calendar Year 50 CY24 45 Clinical Trials Revenue $44.2m, up 21% Growth driven by: 40 • Run-off of strong contracted revenue backlog US$ Million 35 • Diversification of project type in 30 contracted revenue backlog (mix of indications and phases) providing faster revenue y
Slide 9: Clinical Trials Sales Contracts, by Half Year
Clinical Trials Sales Contracts, by Half Year 60 1H25 Clinical Trials Sales Contracts $20.3m 50 • Alzheimer’s $14.2m ➢ 1H24 $6.7m 40 ➢ US$ Million 2H24 $4.1m • Other indications $6.1m 30 ➢ 1H24 $4.2m ➢ 2H24 $11.9m 20 • Across all indications, seeing an increased number of opportunities, reflecting:
Slide 10: Profitable Growth
Profitable Growth Gross Profit Margin & EBIT Margin percentages expected to be consistent with 2H24 – the most recent half-year • Technology investment over the last two years continues to drive efficiency gains across the business • Notwithstanding increasing revenue, the number of fulltime employe
Slide 11: Capital Management
Capital Management Cash Balance 31-Dec-24: $34.2m Up from $30.1m at 30-Jun-24 Up from $25.3m at 31-Dec-23 Increase driven by operating cashflow • Receipts from Eisai under Healthcare agreement consistent over last two years • No capital raised, other than small number of employee share options exerc
Slide 12: Cogstate Strategy Overview
Cogstate Digital Brain Health Strategy Cogstate Strategy Overview Market Dynamics & Cogstate Positioning Offering Alzheimer’s represents generational Software opportunity • Proprietary digital assessments • Advanced data analytic offerings for automated quality assurance Leveraging partnerships to e
Slide 13: Cogstate Offering In Clinical Trials
Cogstate Offering In Clinical Trials We help sponsors make decisions about their drug candidates (“Does it work?” “Is it safe?”). To make decisions they need conclusive, reliable data. We continue to develop new solutions to minimize error in clinical outcome assessments to help get safe and effecti
Slide 14: Cogstate Portfolio of Ongoing Clinical Trials
Cogstate Portfolio of 99 Ongoing Clinical Trials Ongoing Trials, Ongoing Trials, by Indication by Phase 45 9 40 35 27 Trials 30 25 43 Trials 4 16 Trials 20 15 10 Alzheimer's 5 Cancer, Metabolic, Healthy & Other 0 Mood & Other Neurological disorders 0 1 2 3 Pediatrics & Rare disease Phase Sleep Disor
Slide 15: Growth Drivers: FY25 & Beyond
Growth Drivers: FY25 & Beyond Cogstate growing Alzheimer’s market share Scale through channel partnerships • Success running important phase 3 Alzheimer’s • Partnered with providers of tech to clinical trials programs provides commercial validation • Partners range in size from $10m - $500m revenue
Slide 16: Cogstate
© Cogstate